POMC and pituitary adenocarcinoma: In 2018, Lin et al. reported about a patient with ACTH-secreting pituitary carcinomas who was successfully treated with combined immunotherapy with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) [36].